Advertisement NABsys raises $4 million in equity financing - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

NABsys raises $4 million in equity financing

NABsys, which is developing an electronic, solid-state DNA sequencing technology, has closed a $4 million equity round led by Point Judith Capital.

Slater Technology Fund and other previous investors also participated in the round. The proceeds will be used to further develop NABsys’s proprietary DNA sequencing platform.

Based on technology developed at and licensed from Brown University, the NABsys DNA sequencing platform combines physical and biochemical methods. It detects electronically the positions of hybridized DNA probes and then uses highly developed algorithms to accurately reconstruct the DNA sequence, said NABsys.

Barrett Bready, president and CEO of NABsys, said: “The technological advantages that the NABsys platform enjoys, namely electronic detection, the use of all solid-state materials, lack of dependence on a polymerase, inherent error checking, and long-range sequence information, will allow the technology to offer clinically relevant cost, speed, and accuracy parameters for whole-genome sequencing.”